Raphael Pharmaceutical (RAPH) Non-Current Debt (2022 - 2026)

Raphael Pharmaceutical has disclosed Non-Current Debt across 5 years of filings, most recently posting $1.3 million for Q2 2026.

• In Q2 2026, Non-Current Debt changed N/A year-over-year to $1.3 million; the TTM figure through Jun 2026 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $946000.0, up 314.91% from the prior year.
• Non-Current Debt came in at $1.3 million for Q2 2026 at Raphael Pharmaceutical, up from $946000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $1.3 million in Q2 2026 to a low of $3000.0 in Q4 2022.
• Average Non-Current Debt over 5 years is $505000.0, with a median of $228000.0 recorded in 2024.
• Year-over-year, Non-Current Debt surged 1166.67% in 2023 and jumped 314.91% in 2025.
• Over 5 years, Non-Current Debt stood at $3000.0 in 2022, then surged by 1166.67% to $38000.0 in 2023, then jumped by 500.0% to $228000.0 in 2024, then jumped by 314.91% to $946000.0 in 2025, then jumped by 38.48% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $1.3 million in Q2 2026, $946000.0 in Q4 2025, and $228000.0 in Q4 2024.